[1]Association AD.10.Cardiovascular disease and risk man agement: Standards of medical care in diabetes-2019[J].Diab  etes Care.2019,42(Suppl 1):S103-S123.  

[2]American Diabetes Association.Standards of Medical Care in Diabetes-2022.Diabetes Care.2022,45(Suppl1):S1-S258.  

[3]Zhao FQ,Keating AF.Functional properties and genomicsof glucose transporters[J].Curr Genomics.2007,8(2):113-128.  

[4]Soták M,Casselbrant A,Rath E,et al.Intestinal sodium/  glucose cotransporter 3 expression is epithelial and downre  gulated in obesity[J].Life Sci,2021,267:118974.  

[5] Kothinti RK, Blodgett AB, North PE, et al. A novel SGLT  is expressed in the human kidney[J].Eur J Pharmacol. 2012,  690(1-3):77-83.  

[6]Tazawa S,Yamato T,Fujikura H,et al. SLC5A9/SGLT4, a new  Na+-dependent glucose transporter,is an essential transpor  ter for mannose,1,5-anhydro-D-glucitol,and fructose[J].Life  Sci.2005,76(9):1039-1050.

[7]Grempler R, Augustin R, Froehner S, et al. Functional  characterisation of human SGLT-5 as a novel kidney-specific  sodium-dependent sugar transporter[J].FEBS Lett.2012,586  (3):248-253.

[8]Lin X, Ma L, Fitzgerald RL, et al.Human Sodium/Inositol  Cotransporter 2 (SMIT2) Transports Inositols But Not Glucose  in L6 Cells[J].Arch Biochem Biophys. 2009, 481(2):197-201.

[9]Kasichayanula S,Liu X,Lacreta F,etal.Clinical Pharmaco  kinetics and Pharmacodynamics of Dapagliflozin, a Selective  Inhibitor of Sodium-Glucose Co-transporter Type 2[J]. Clin  Pharmacokinet.2014,53(1):17-27.

[10]El-Sayed N,Mostafa YM,AboGresha NM,et al.Dapaglifloz  in attenuates diabetic cardiomyopathy through erythropoie  tin up-regulation of AKT/JAK/MAPK pathways in streptozotocin  -induced diabetic rats[J].Chem Biol Interact.2021,347:109617. [11] Uthman L, Baartscheer A, Bleijlevens B, et al. Class  effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic  Na+ and vasodilation[J].Diabetologia.2018,61(3):722-726.

[12]Sato T,Aizawa Y,Yuasa S,et al.The effect of dapaglifl  ozin treatment on epicardial adipose tissue volume[J]. Cardi  ovasc Diabetol.2018,Jan4;17(1):6.

[13]Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of  Dapagliflozin on Atrial Fibrillation in Patients With Type 2  Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial[J].  Circulation.2020,141(15):1227-1234.

[14]Devineni D,Polidori D.Clinical Pharmacokinetic, Phar  macodynamic, and Drug–Drug Interaction Profile of Canaglif  lozin, a Sodium-Glucose Co-transporter 2 Inhibitor[J]. Clin  Pharmacokinet.2015, 54(10):1027-1041.

[15]Weir MR, McCullough PA, Buse JB, et al. Renal and  Cardiovascular Effects of Sodium Glucose Co-Transporter 2  Inhibitors in Patients with Type 2 Diabetes and Chronic  Kidney Disease: Perspectives on the Canagliflozin and Renal  Events in Diabetes with Established Nephropathy ClinicalEvaluation Trial Results[J].Am J Nephrol.2020,51(4):276-288.

[16]Kondo H, Akoumianakis I, Badi I, et al. Effects of  canagliflozin on human myocardial redox signalling: clinical  implications[J].Eur Heart J.2021,42(48):4947-4960.

[17]Sayour AA, Korkmaz-Icöz S, Loganathan S, et al. Acute  canagliflozin treatment protects against in vivo myocardial  ischemia-reperfusion injury in non-diabetic male rats and  enhances endothelium-dependent vasorelaxation[J]. J Transl  Med.2019,17(1):127.

[18]Ashry NA,Abdelaziz RR,Suddek GM,et al.Canagliflozin  ameliorates aortic and hepatic dysfunction in dietary-induc  ed hypercholesterolemia in the rabbit[J]. Life Sci. 2021, 280:  119731.

[19]Behnammanesh G,Durante GL,Khanna YP,et al.Canagliflo  zin inhibits vascular smooth muscle cell proliferation and  migration: Role of heme oxygenase-1[J]. Redox Biol. 2020, 32:  101527.

[20] Tahara A, Kurosaki E, Yokono M, et al. Pharmacological  profile of ipragliflozin (ASP1941), a novel selective SGLT2  inhibitor, in vitro and in vivo[J]. Naunyn Schmiedebergs Arch  Pharmacol.2012,385(4):423-436.

[21] Ito H, Okamoto R, Ali Y, et al. Cardiorenal protective  effects of sodium-glucose cotransporter 2 inhibition in com  bination with angiotensin II type 1 receptor blockade in salt  -sensitive Dahl rats[J].J Hypertens.2022,40(5):956-968.

[22] Kang SM, Yun HM, Sohn M, et al. Vascular and metabolic  effects of ipragliflozin versus sitagliptin (IVS) in type 2  diabetes treated with sulphonylurea and metformin: IVS  study[J].Diabetes Obes Metab.2023,18.

[23]Akasaka H, Sugimoto K, Shintani A, et al. Effects of  ipragliflozin on left ventricular diastolic function in patie  nts with type 2 diabetes and heart failure with preserved  ejection fraction: The EXCEED randomized controlled multice  nter study[J].Geriatr Gerontol Int.2022,22(4):298-304.

[24]谢少斐,张凤逸,邹珊,等.已上市钠-葡萄糖协同转运蛋 白2抑制剂临床药动学特点比较[J].中国现代应用药学,2016,33  (04):517-520. [25]Bouchi R,Terashima M,Sasahara Y,et al.Luseogliflozin  reduces epicardial fat accumulation in patients with type 2  diabetes:a pilot study[J].Cardiovasc Diabetol.2017,16(1):32.

[26]Mori Y,Terasaki M,Hiromura M,et al.Luseogliflozin  attenuates neointimal hyperplasia after wire injury in highfat diet-fed mice via inhibition of perivascular adipose  tissue remodeling[J].Cardiovasc Diabetol.2019,18(1):143.

[27]Nakashima M,Miyoshi T,Ejiri K,et al.Effects of luseog  liflozin on estimated plasma volume in patients with heartfailure with preserved ejection fraction[J]. ESC Heart Fail.  2022,9(1):712-720.

[28]Seino Y. Luseogliflozin for the treatment of type 2  diabetes[J].Expert Opin Pharmacother.2014,15(18):2741-2749. [29]Scheen AJ.Pharmacokinetic and pharmacodynamic prof  ile of empagliflozin, a sodium glucose co-transporter 2 inhib  itor[J].Clin Pharmacokinet.2014,53(3):213-225.

[30] Tikkanen I, Narko K, Zeller C, et al. Empagliflozin  reduces blood pressure in patients with type 2 diabetes and  hypertension[J].Diabetes Care.2015,38(3):420-428.

[31]Shao Q, Meng L, Lee S, et al. Empagliflozin, a sodium  glucose co-transporter-2 inhibitor, alleviates atrial remod  eling and improves mitochondrial function in high-fat diet  /streptozotocin-induced diabetic rats[J].Cardiovasc Diabetol.  2019,18(1):165. [32] Santos-Gallego CG, Requena-Ibanez JA, San Antonio  R, et al. Empagliflozin Ameliorates Adverse Left Ventricular  Remodeling in Nondiabetic Heart Failure by Enhancing  Myocardial Energetics[J].2019,73(15):1931-1944.

[33]Andreadou I,Efentakis P,Balafas E,et al. Empagliflozin  Limits Myocardial Infarction in Vivo and Cell Death in Vitro:  Role of STAT3, Mitochondria, and Redox Aspects[J]. Front  Physiol.2017,8:1077.

[34]Yurista SR, Silljé HHW, Oberdorf-Maass SU, et al.  Sodium-glucose co-transporter 2 inhibition with empaglifloz  in improves cardiac function in non-diabetic rats with left  ventricular dysfunction after myocardial infarction[J]. Eur J  Heart Fail.2019,21(7):862-873.

[35] Herat LY, Matthews VB, Magno AL, et al. An evaluation  of empagliflozin and it's applicability to hypertension as a  therapeutic option[J].Expert Opin Pharmacother.2020,21(10):  1157-1166.

[36]von Lewinski D,Kolesnik E,Tripolt NJ,et al.Empagliflozin in acute myocardial infarction: the EMMY trial[J]. Eur  Heart J.2022,43(41):4421-4432.

[37] Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy  of Ertugliflozin on Heart Failure-Related Events in Patients  With Type 2 Diabetes Mellitus and Established Atherosclerotic  Cardiovascular Disease: Results of the VERTIS CV Trial[J].  Circulation. 2020,142(23):2205-2215.

[38]Moellmann J,Mann PA,Kappel BA,et al.The sodium-gluco  se co-transporter-2 inhibitor ertugliflozin modifies the  signature of cardiac substrate metabolism and reduces card  iac mTOR signalling, endoplasmic reticulum stress and apopto  sis[J].Diabetes Obes Metab.2022,24(11):2263-2272.

[39]Markham A,Keam SJ.Sotagliflozin:First Global Approval  [J]Drugs.2019,79(9):1023-1029.

[40]Koufakis T, Mustafa OG, Tsimihodimos V, et al. Insights  Into the Results of Sotagliflozin Cardiovascular Outcome  Trials:Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?[J].Drugs.2021,81(12):1365-1371.

[41]Vallianou NG, Christodoulatos GS, Kounatidis D,et al.  Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart  of the problem[J].Metabol Open.2021,10:100089.

[42] Bode D, Semmler L, Wakula P , et al. Dual SGLT-1 and  SGLT-2 inhibition improves left atrial dysfunction in HFpEF  [J].Cardiovasc Diabetol.2021,20(1):7.

[43]Posch MG, Walther N, Ferrannini E, et al. Metabolic,  Intestinal,and Cardiovascular Effects of Sotagliflozin Comp  ared With Empagliflozin in Patients With Type 2 Diabetes: A  Randomized, Double-Blind Study[J].Diabetes Care.2022,45(9):  2118-2126.